Seminars in Oncology
Volume 31, Issue 5 , Pages 702-713, October 2004

Cognitive sequelae of brain radiation in adults

  • Nadia N. Laack

      Affiliations

    • Division of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • ,
  • Paul D. Brown

      Affiliations

    • Division of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
    • Corresponding Author InformationAddress reprint requests to Paul D. Brown, MD, 200 First St SW, Rochester, MN 55905.

Radiotherapy (RT) is a proven curative and palliative therapeutic tool in the treatment of a wide variety of primary and metastatic brain tumors in adults. Recent advances in multimodality therapy have led to improvement in survival for many cancer patients. As survival has improved, more attention has been directed toward long-term treatment-related morbidity. Specifically, the effect of RT on the long-term cognitive performance of these patients is a major concern. This article reviews the neurocognitive effects of cranial RT on adult patients with brain tumors. Analyses of neurocognitive function are confounded by factors such as surgery, chemotherapy, tumor characteristics, tumor progression, concurrent medical illnesses, neurologic comorbidity, and medications that can contribute to neurocognitive deficits. Risk of deficits after cranial RT is associated with high RT dose, large fraction size, larger field size, and extremes of age at time of treatment. Using modern techniques with moderate total doses (50 to 54 Gy), conformal RT, conventional fractionation, and advanced planning imaging and software, the risks of neurocognitive deficits are quite small and greatly overshadowed by deficits caused by the tumor itself. Further studies need to be undertaken to elucidate the degree and cause of cognitive decline in adult patients undergoing multimodality therapy for cranial tumors.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(04)00335-5

doi:10.1053/j.seminoncol.2004.07.013

Seminars in Oncology
Volume 31, Issue 5 , Pages 702-713, October 2004